Cargando…

Comparison of the clinical features and long-term prognosis of gallbladder neuroendocrine carcinoma versus gallbladder adenocarcinoma: A propensity score-matched analysis

Gallbladder neuroendocrine carcinoma (GBNEC) is rare and characterized by a low degree of tumor differentiation. The clinical features of GBNEC versus gallbladder adenocarcinoma (GBADC) remain a subject of debate. A total of 201 GBADC and 36 GBNEC cases that underwent surgery resection between Janua...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Ya-Fei, Ma, Wen-Jie, Hu, Hai-Jie, Gu, Han-Fei, Jin, Yan-Wen, Li, Fu-Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10655887/
https://www.ncbi.nlm.nih.gov/pubmed/37724922
http://dx.doi.org/10.17305/bb.2023.9582
_version_ 1785147996306931712
author Hu, Ya-Fei
Ma, Wen-Jie
Hu, Hai-Jie
Gu, Han-Fei
Jin, Yan-Wen
Li, Fu-Yu
author_facet Hu, Ya-Fei
Ma, Wen-Jie
Hu, Hai-Jie
Gu, Han-Fei
Jin, Yan-Wen
Li, Fu-Yu
author_sort Hu, Ya-Fei
collection PubMed
description Gallbladder neuroendocrine carcinoma (GBNEC) is rare and characterized by a low degree of tumor differentiation. The clinical features of GBNEC versus gallbladder adenocarcinoma (GBADC) remain a subject of debate. A total of 201 GBADC and 36 GBNEC cases that underwent surgery resection between January 2010 and 2022 at the Department of Biliary Surgery, West China Hospital, Sichuan University were included. A 1:1 propensity score matching (PSM) was performed based on seven predefined variables: age, sex, the American Joint Committee on Cancer (AJCC) stage, resection status, perineural invasion (PNI), lymphovascular invasion (LVI), and degree of tumor differentiation. Compared with GBADC, GBNEC patients were younger (median age 56.0 vs 64.0 years; P ═ 0.001), and more patients presented with advanced stages of tumor (P ═ 0.003). Patients with GBNEC also had a higher rate of PNI (55.6% vs 22.4%; P < 0.001), and LVI (63.9% vs 45.80%; P ═ 0.658). Before PSM, GBNEC patients had inferior prognoses compared with GBADC patients with a shorter median overall survival (mOS) (15.02 vs 20.11 months; P ═ 0.0028) and a shorter median recurrence-free survival (mRFS) (10.30 vs 15.17 months; P ═ 0.0028). However, after PSM analyses, there were no differences in OS (mOS 18.6 vs 18.0 months; P ═ 0.24) or RFS (mRFS 10.98 vs 12.02 months; P ═ 0.39) between the GBNEC and GBADC cases. After multivariate analysis, tumor diagnosis (GBNEC vs GBADC) was not identified as an independent risk factor for shorter RFS (P ═ 0.506) or OS (P ═ 0.731). Unfavorable pathological features, including advanced AJCC tumor stages, poor differentiation, presence of LVI, and positive resection margins (all P < 0.05), were independent risk factors for inferior OS and RFS. GBNEC is difficult to diagnose early and has a prognosis comparable to stage-matched poorly differentiated GBADC. Tumor diagnosis (either GBADC or GBNEC) was not an independent risk factor for the patient’s OS. Unfavorable pathological features of the neoplasm are the main determinants.
format Online
Article
Text
id pubmed-10655887
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
record_format MEDLINE/PubMed
spelling pubmed-106558872023-12-01 Comparison of the clinical features and long-term prognosis of gallbladder neuroendocrine carcinoma versus gallbladder adenocarcinoma: A propensity score-matched analysis Hu, Ya-Fei Ma, Wen-Jie Hu, Hai-Jie Gu, Han-Fei Jin, Yan-Wen Li, Fu-Yu Biomol Biomed Research Article Gallbladder neuroendocrine carcinoma (GBNEC) is rare and characterized by a low degree of tumor differentiation. The clinical features of GBNEC versus gallbladder adenocarcinoma (GBADC) remain a subject of debate. A total of 201 GBADC and 36 GBNEC cases that underwent surgery resection between January 2010 and 2022 at the Department of Biliary Surgery, West China Hospital, Sichuan University were included. A 1:1 propensity score matching (PSM) was performed based on seven predefined variables: age, sex, the American Joint Committee on Cancer (AJCC) stage, resection status, perineural invasion (PNI), lymphovascular invasion (LVI), and degree of tumor differentiation. Compared with GBADC, GBNEC patients were younger (median age 56.0 vs 64.0 years; P ═ 0.001), and more patients presented with advanced stages of tumor (P ═ 0.003). Patients with GBNEC also had a higher rate of PNI (55.6% vs 22.4%; P < 0.001), and LVI (63.9% vs 45.80%; P ═ 0.658). Before PSM, GBNEC patients had inferior prognoses compared with GBADC patients with a shorter median overall survival (mOS) (15.02 vs 20.11 months; P ═ 0.0028) and a shorter median recurrence-free survival (mRFS) (10.30 vs 15.17 months; P ═ 0.0028). However, after PSM analyses, there were no differences in OS (mOS 18.6 vs 18.0 months; P ═ 0.24) or RFS (mRFS 10.98 vs 12.02 months; P ═ 0.39) between the GBNEC and GBADC cases. After multivariate analysis, tumor diagnosis (GBNEC vs GBADC) was not identified as an independent risk factor for shorter RFS (P ═ 0.506) or OS (P ═ 0.731). Unfavorable pathological features, including advanced AJCC tumor stages, poor differentiation, presence of LVI, and positive resection margins (all P < 0.05), were independent risk factors for inferior OS and RFS. GBNEC is difficult to diagnose early and has a prognosis comparable to stage-matched poorly differentiated GBADC. Tumor diagnosis (either GBADC or GBNEC) was not an independent risk factor for the patient’s OS. Unfavorable pathological features of the neoplasm are the main determinants. Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina 2023-12-01 2023-12-01 /pmc/articles/PMC10655887/ /pubmed/37724922 http://dx.doi.org/10.17305/bb.2023.9582 Text en © 2023 Hu et al. https://creativecommons.org/licenses/by/4.0/This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/).
spellingShingle Research Article
Hu, Ya-Fei
Ma, Wen-Jie
Hu, Hai-Jie
Gu, Han-Fei
Jin, Yan-Wen
Li, Fu-Yu
Comparison of the clinical features and long-term prognosis of gallbladder neuroendocrine carcinoma versus gallbladder adenocarcinoma: A propensity score-matched analysis
title Comparison of the clinical features and long-term prognosis of gallbladder neuroendocrine carcinoma versus gallbladder adenocarcinoma: A propensity score-matched analysis
title_full Comparison of the clinical features and long-term prognosis of gallbladder neuroendocrine carcinoma versus gallbladder adenocarcinoma: A propensity score-matched analysis
title_fullStr Comparison of the clinical features and long-term prognosis of gallbladder neuroendocrine carcinoma versus gallbladder adenocarcinoma: A propensity score-matched analysis
title_full_unstemmed Comparison of the clinical features and long-term prognosis of gallbladder neuroendocrine carcinoma versus gallbladder adenocarcinoma: A propensity score-matched analysis
title_short Comparison of the clinical features and long-term prognosis of gallbladder neuroendocrine carcinoma versus gallbladder adenocarcinoma: A propensity score-matched analysis
title_sort comparison of the clinical features and long-term prognosis of gallbladder neuroendocrine carcinoma versus gallbladder adenocarcinoma: a propensity score-matched analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10655887/
https://www.ncbi.nlm.nih.gov/pubmed/37724922
http://dx.doi.org/10.17305/bb.2023.9582
work_keys_str_mv AT huyafei comparisonoftheclinicalfeaturesandlongtermprognosisofgallbladderneuroendocrinecarcinomaversusgallbladderadenocarcinomaapropensityscorematchedanalysis
AT mawenjie comparisonoftheclinicalfeaturesandlongtermprognosisofgallbladderneuroendocrinecarcinomaversusgallbladderadenocarcinomaapropensityscorematchedanalysis
AT huhaijie comparisonoftheclinicalfeaturesandlongtermprognosisofgallbladderneuroendocrinecarcinomaversusgallbladderadenocarcinomaapropensityscorematchedanalysis
AT guhanfei comparisonoftheclinicalfeaturesandlongtermprognosisofgallbladderneuroendocrinecarcinomaversusgallbladderadenocarcinomaapropensityscorematchedanalysis
AT jinyanwen comparisonoftheclinicalfeaturesandlongtermprognosisofgallbladderneuroendocrinecarcinomaversusgallbladderadenocarcinomaapropensityscorematchedanalysis
AT lifuyu comparisonoftheclinicalfeaturesandlongtermprognosisofgallbladderneuroendocrinecarcinomaversusgallbladderadenocarcinomaapropensityscorematchedanalysis